Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A known ✓ | P28223 | 8/20 | 0.97 |
| ▸ | HTR1D known ✓ | P28221 | 8/20 | 0.97 |
| ▸ | HTR1A known ✓ | P08908 | 8/20 | 0.67 |
| ▸ | HTR2C known ✓ | P28335 | 3/20 | 0.67 |
| ▸ | HTR2B known ✓ | P41595 | 2/20 | 0.67 |
| ▸ | HTR1B known ✓ | P28222 | 5/20 | 0.65 |
| ▸ | HTR7 known ✓ | P34969 | 3/20 | 0.64 |
| ▸ | HTR6 known ✓ | P50406 | 2/20 | 0.64 |
| ▸ | HTR4 known ✓ | Q13639 | 2/20 | 0.64 |
| ▸ | HTR3E known ✓ | A5X5Y0 | 1/20 | 0.64 |
| ▸ | HTR3B known ✓ | O95264 | 1/20 | 0.64 |
| ▸ | DRD1 known ✓ | P21728 | 1/20 | 0.64 |
| ▸ | HTR1E known ✓ | P28566 | 1/20 | 0.64 |
| ▸ | HTR1F known ✓ | P30939 | 1/20 | 0.64 |
| ▸ | DRD3 known ✓ | P35462 | 1/20 | 0.64 |
| ▸ | HTR3A known ✓ | P46098 | 1/20 | 0.64 |
| ▸ | HTR5A known ✓ | P47898 | 1/20 | 0.64 |
| ▸ | SLC18A2 known ✓ | Q05940 | 1/20 | 0.64 |
| ▸ | HTR3D known ✓ | Q70Z44 | 1/20 | 0.64 |
| ▸ | HTR3C known ✓ | Q8WXA8 | 1/20 | 0.64 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30867163 | 0.98 | HTR1D (1.00) | HTR2AHTR1DHTR1AHTR2CNPSR1 | |
| SCHEMBL1129793 | 0.98 | HTR1D (1.00) | HTR2AHTR1DHTR1AHTR2CNPSR1 | |
| Iodide SCHEMBL27075559 | 0.97 | HTR1D (0.97) | HTR2AHTR1DHTR1AHTR2CNPSR1 | |
| Cyanide SCHEMBL28696057 | 0.94 | HTR1D (0.91) | HTR2AHTR1DHTR1AHTR2CNPSR1 | |
| SCHEMBL1520131 | 0.89 | HTR2A (0.82) | HTR2AHTR1DHTR1AHTR2CHTR2B | |
| Hydrochloric Acid SCHEMBL6087688 | 0.87 | HTR2A (0.97) | HTR2AHTR1DHTR1AHTR2CNPSR1 | |
| SCHEMBL7325323 | 0.86 | HTR2A (0.77) | HTR2AHTR1DHTR1AHTR2CNPSR1 | |
| SCHEMBL1971468 | 0.85 | HTR2A (1.00) | HTR2AHTR1DHTR1AHTR2CNPSR1 | |
| Hydrochloric Acid SCHEMBL8868843 | 0.84 | TRPM8 (0.76) | HTR2AHTR1DHTR1AHTR2CNPSR1 | |
| SCHEMBL8344495 | 0.83 | HTR1D (0.73) | HTR2AHTR1DHTR1AHTR2CHTR2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 157 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240279175-A1 | CRYSTALLINE HYDROCHLORIDE SALTS OF SUBSTITUTED TRYPTAMINES | CAAMTECH, INC. | 2024-08-22 | — | — | US | claimed |
| CN-110156846-A | A kind of preparation process of D-galactosamine hydrochloride | 南京博源医药科技有限公司 | 2019-08-23 | — | — | CN | claimed |
| CN-108623511-A | A kind of indole amides class compound can be used for treating cancer | 南华大学 | 2018-10-09 | — | — | CN | claimed |
| EP-1420021-A1 | DNA Methyltransferase inhibitors | The Penn State Research Foundation (US) | 2004-05-19 | — | — | EP | claimed |
| CN-1370170-A | DNA methyltransferase inhibitors | PENN STATE RES FOUND (US) | 2002-09-18 | — | — | CN | claimed |
| EP-0743574-B1 | Migration imaging members | XEROX CORP (US) | 2000-12-27 | — | — | EP | claimed |
| EP-0743573-B1 | Method for obtaining image contrast migration imaging members | XEROX CORP (US) | 2000-09-06 | — | — | EP | claimed |
| EP-0743573-A2 | Method for obtaining image contrast migration imaging members | XEROX CORPORATION (US) | 1996-11-20 | — | — | EP | claimed |
| EP-0743574-A2 | Migration imaging members | XEROX CORPORATION (US) | 1996-11-20 | — | — | EP | claimed |
| US-5563014-A | SOFTENABLE LAYER CONTAINIG PHOTOSENSITIVE MARKING MATERIAL; TRANSPARENTIZING AGENT | XEROX CORPORATION (US) | 1996-10-08 | — | — | US | claimed |
| US-5514505-A | SELECTIVE TRANSPARENTIZATION OF PHOTOSENSITIVE MIGRATION MARKING PARTICLES EMBEDDED NEAR THE SURFACE OF A SOFTENABLE LAYER SUPPORTED BY AN ELECTROCONDUCTIVE SUBSTRATE | XEROX CORPORATION (US) | 1996-05-07 | — | — | US | claimed |
| US-20250326719-A1 | FUSED BICYCLIC ALKYLENE LINKED IMIDODICARBONIMIDIC DIAMIDES, METHODS FOR SYNTHESIS, AND USES IN THERAPY | NOVATARG INC (US) | 2025-10-23 | — | — | US | disclosed |
| US-20250257033-A1 | METHYL SUBSTITUTED QUATERNARY TRYPTAMINE DERIVATIVES | CAAMTECH INC (US) | 2025-08-14 | — | — | US | disclosed |
| US-12371404-B2 | Fused bicyclic alkylene linked imidodicarbonimidic diamides, methods for synthesis, and uses in therapy | NOVATARG, INC. (US) | 2025-07-29 | — | — | US | disclosed |
| EP-4561990-A1 | METHYL SUBSTITUTED QUATERNARY TRYPTAMINE DERIVATIVES | Caamtech, Inc. (US) | 2025-06-04 | — | — | EP | disclosed |
| WO-1990014827-A1 | METHOD OF SUPPRESSING APPETITE BY ADMINISTRATION OF TETRAHYDRO-β-CARBOLINE DERIVATIVES | NEUREX CORPORATION (US) | 1990-12-13 | — | — | WO | disclosed |
| US-4358451-A | ANOXIA, PSYCHOTROPIC | SYNTHELABO (FR) | 1982-11-09 | — | — | US | disclosed |
| US-4336256-A | TREATMENT OF ANOXIA, DEPRESSION AND IN PSYCHOTROPIC THERAPY | SYNTHELABO (FR) | 1982-06-22 | — | — | US | disclosed |
| US-4272539-A | ANOXIA, ANTIDEPRESSANTS | SYNTHELABO (FR) | 1981-06-09 | — | — | US | disclosed |
| US-4138489-A | FORMALDEHYDE, QUATERNIZATION | AGENCE NATIONALE DE VALORISATION DE LA RECHERCHE (ANVAR) (FR) | 1979-02-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250326719-A1 | FUSED BICYCLIC ALKYLENE LINKED IMIDODICARBONIMIDIC DIAMIDES, METHODS FOR SYNTHESIS, AND USES IN THERAPY | SLC16A7, SLC16A1, HADHB | HTR2A 3926/4885HTR1D 4314/4885HTR1A 4374/4885 |
| US-20250257033-A1 | METHYL SUBSTITUTED QUATERNARY TRYPTAMINE DERIVATIVES | INMT, TMT1A, SLC6A4 | HTR2A 75/4885HTR1D 89/4885HTR1A 22/4885 |
| US-12371404-B2 | Fused bicyclic alkylene linked imidodicarbonimidic diamides, methods for synthesis, and uses in therapy | SLC16A7, SLC16A1, HADHB | HTR2A 3926/4885HTR1D 4314/4885HTR1A 4374/4885 |
| US-20240279175-A1 | CRYSTALLINE HYDROCHLORIDE SALTS OF SUBSTITUTED TRYPTAMINES | SLC6A4, HTR2A, CMA1 | HTR2A 2/4885HTR1D 34/4885HTR1A 11/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.